![]() |
|
|
Vol. 56, Issue 5, 886-894, November 1999
Departments of Pharmacology (Z.D.L., G.W., S.C., P.T.) and Medicine (Y.W., K.R.C.), University of California-San Diego, La Jolla, California
| |
Summary |
|---|
|
|
|---|
Treatment of C2-C12 mouse myoblasts with the immunosuppressant drug cyclosporin A (CsA) enhances the increase in acetylcholinesterase (AChE) expression observed during skeletal muscle differentiation. The enhanced AChE expression is due primarily to increased mRNA stability because CsA treatment increases the half-life of AChE mRNA, but not the apparent transcriptional rate of the gene. Neither tacrolimus (FK506), an immunosuppressive agent with a distinct structure, nor cyclosporine H, an inactive congener of CsA, alters AChE expression. The enhanced AChE expression is associated with the muscle differentiation process, but cannot be triggered by CsA exposure before differentiation. Myoblasts and myotubes of C2-C12 cells express similar amounts of cyclophilin A and FKBP12, immunophilins known to be intracellular-binding targets for CsA and tacrolimus, respectively. However, cellular levels of calcineurin, a calcium/calmodulin-dependent phosphatase known to be the cellular target of ligand-immunophilin complexes, increase 3-fold during myogenesis. Overexpression of constitutively active calcineurin in differentiating cells reduces AChE mRNA levels and CsA antagonizes such an inhibition. Conversely, overexpression of a dominant negative calcineurin construct increases AChE mRNA levels, which are further enhanced by CsA. Thus, a CsA sensitive, calcineurin mediated pathway appears linked to differentiation-induced stabilization of AChE mRNA during myogenesis.
| |
Introduction |
|---|
|
|
|---|
Differentiation
of skeletal muscle from myoblasts to myotubes is globally controlled by
the expression of muscle-specific genes of the myo D family. However,
following initiation of differentiation, expression of genes encoding
proteins important for controlling cellular excitability, such as
acetylcholinesterase (AChE) and nicotinic acetylcholine receptors
(nAChR), occurs through distinct mechanisms. Although the increased
expression of nAChR arises from enhancement of its transcription rate
(Evans et al., 1987
; Baldwin and Burden, 1988
), the expression of AChE
appears mainly due to stabilization of a labile AChE mRNA (Fuentes and
Taylor, 1993
; Luo et al., 1994
).
Previous studies indicated that regulation of intracellular
Ca2+ through L-type Ca2+
channels in the plasma membrane or intracellular ryanodine-sensitive Ca2+ channels plays an important role in
stabilization of AChE transcripts during muscle development in mouse
C2-C12 myocytes (Luo et al., 1994
) and in intact mouse skeletal muscle
(Luo et al., 1996
). Other studies revealed that immunosuppressant
cyclosporin A (CsA) regulates mRNA stability of interleukin-3
(Nair et al., 1994
). Furthermore, FKBP12, an intracellular
receptor for another immunosuppressant tacrolimus (FK506), was
copurified with ryanodine receptors (Jayaraman et al., 1992
) and found
to modulate intracellular calcium release by stabilizing
ryanodine-sensitive calcium channels in skeletal muscle (Timerman et
al., 1993
; Brillantes et al., 1994
).
CsA and tacrolimus bind to intracellular immunophilins such as
cyclophilin A and FKBP12, respectively (Handschumacher et al., 1984
;
Harding et al., 1989
; Standaert et al., 1990
). The immediate cellular
target for the complexes of CsA-cyclophilin and FK506-FKBP12, but not
for the complexes of CsA-FKBP12 or FK506-cyclophilin, is calcineurin, a
Ca2+/calmodulin-dependent protein phosphatase
(Liu et al., 1991
). The influence of CsA and tacrolimus on regulation
of mRNA stability in other systems and the linkage of their
intracellular receptors to intracellular Ca2+
mobilization prompted us to investigate the functional role of the
calcineurin-mediated pathway in regulation of AChE mRNA stabilization during myogenesis.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
CsA and cyclosporine H (CsH) were from Sandoz
Ltd. (Basel, Switzerland). A stock solution of CsA and CsH was
dispensed in ethanol and Tween 80 followed by addition of PBS.
Tacrolimus was from Fujisawa Ireland, Ltd. (Kerry, Ireland). Ethanol
stock solutions were further diluted into culture medium at the time of
treatment. Bicinchoninic acid (BCA) protein assay reagents were from
Pierce Chemical Co. (Rockford, IL). The creatine kinase assay materials and all other chemicals were from Sigma Chemical Co. (St. Louis, MO).
Components of culture medium were from Gibco Laboratories (Grand
Island, NY). [
-125I]Bungarotoxin
([
-125I]BTX; specific activity 14.5 µCi/µg) was from NEN Research Products (Wilmington, DE).
32P-
-UTP (specific activity ~800 Ci/mmol)
was from Amersham Corp. (Arlington Heights, IL). The polyclonal
anticyclophilin A antibody was from Affinity BioReagents, Inc.
(Neshanic Station, NJ), the monoclonal anticalcineurin antibody was
from Transduction Laboratories (Lexington, KY), the anti-FKBP12
antibody was a gift from Dr. Steven J. Burakoff at the Dana-Farber
Cancer Institute (Boston, MA) and the antihemagglutinin (HA)
antibody was a gift from Dr. Michael Karin at the University of
California-San Diego. The secondary antibody and detection reagents
were from Amersham Corp. (Buckinghamshire, England). Tris-glycine
polyacrylamide gels were from NOVEX (San Diego, CA).
Tissue Culture.
C2-C12 cells (American Type Culture
Collection, Rockville, MD) were stored at
70°C and cultured at
37°C, with 5% CO2 in Dulbecco's modified
Eagle's medium containing 20% fetal bovine serum; 0.5% chick embryo
extract; and 1% penicillin, streptomycin, and amphotericin B stock
solution (Antibiotic-Antimycotic; Gibco Laboratories). Cells were
passed either two or three times before plating. Differentiation from
myoblasts to myotubes was induced at ~70% confluence by replacing the high serum medium with Dulbecco's modified Eagle's medium containing 2% horse serum and 1% of the above-mentioned antimicrobial stock solution. To measure secreted AChE in the medium, cells were
differentiated in medium containing serum pretreated with 0.1 mM
diisopropyl fluorophosphate (DFP) to inhibit serum esterase activity.
The DFP-treated serum was incubated overnight at room temperature,
sterile filtered and held for at least 48 h at 4°C, and then
assayed for residual DFP and AChE activity. Such treatment results in
>99% inhibition of serum esterase activity with no inhibitory
activity toward exogenously added AChE activity (Coleman and Taylor,
1996
).
RNA Extraction and RNase Protection Assay.
Total RNA was
extracted from cultured cells with TRIzol reagent from Gibco
Laboratories and stored at
20°C. mRNAs encoding AChE and the
-subunit of nAChR (
-nAChR) were quantified by RNase protection as
described in Luo et al. (1998)
. The antisense probe of AChE mRNA was
made from a mouse Ache cDNA subcloned in Bluescript SK II
plasmids and linearized with XhoI. This probe allows us to
distinguish exon 4 to 6 spliced AChE mRNA from other splice variants. A
fully protected probe in RNase protection assays indicates the presence
of exon 4 to 6 spliced AChE mRNA, whereas the two shorter protected
fragments represent other splice variants (Luo et al., 1998
). A probe
made from a 1.7-kilobase mouse nAChR
subunit cDNA (kindly provided
by Drs. Jim Boulter and Stephen Heinemann, Salk Institute, San Diego,
CA), cloned in pSP-65 and linearized with XhoI, was used to
hybridize with mRNA of the
-nAChR subunit. To normalize for sample
loading, a probe was made from a 316-bp cDNA fragment of the mouse
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from Ambion, Inc.
(Austin, TX). Molecular masses of the protected probes were estimated
by electrophoresis on polyacrylamide gels. Densities of bands were
quantified by densitometry (UltroScan XL; Pharmacia LKB Biotechnology
Inc., Picataway, NJ) and standardized by ratios to the GAPDH bands.
Determination of AChE Activity.
AChE was extracted from
rinsed C2-C12cells in 0.01 M sodium phosphate buffer containing 1 M
NaCl, 1% Triton X-100, 0.01 M ethylene glycol bis(
-aininoethyl
ester)-N,N,N',N'-tetraacetic acid, and a spectrum of protease inhibitors, and protein concentrations were determined with BCA reagents. AChE in the media was concentrated >10-fold in Centriprep 30 concentrators (Amicon Corp., Beverly, MA).
Enzyme activity was determined at room temperature as described by
Ellman et al. (1961)
in 0.1 M sodium phosphate buffer (pH 7.0) containing 0.3 mM 5,5'-dithiobis-(2-nitrobenzoic)acid, 0.5 mM acetylthiocholine iodide, and 0.05 to 0.1 ml of cell extract or concentrated medium. More than 90% of the enzyme activity is due to
AChE as determined from the presence of 10 µM BW284c51 (data not shown).
Determination of Creatine Kinase Activity. Rinsed C2-C12 myotubes differentiated for 3 days were extracted in PBS containing 0.5% Triton X-100 and a spectrum of protease inhibitors. After sonication and centrifugation, supernatants were assayed for protein concentrations with BCA reagents and for creatine kinase activity with Sigma Diagnostics Procedure 520.
-Galactosidase (
-Gal) Staining.
C2-C12 cells infected
with adenovirus containing the lac-Z gene were stained for
-gal
activity as described by Sanes et al. (1986)
. Briefly, infected cells
were rinsed with PBS and fixed for 5 min on ice in PBS containing 2%
formaldehyde and 0.2% glutaraldehyde. After washing, the cells were
overlaid with a PBS reaction mixture containing 1 mg/ml
4-Cl-5-Br-3-indolyl-
-galactosidase, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM MgCl2 and incubated at 37°C until desired color intensity was achieved. The
cells were then fixed for 10 min at room temperature, rinsed, and
stored in PBS.
Determination of nAChR Expression.
Densities of cell surface
nAChR were monitored by binding of
[
-125I]BTX to intact cells cultured in
six-well plates at room temperature. Cells were washed with
differentiation medium and incubated for 10 min in the presence or
absence of 10 mM carbamylcholine chloride. [
-125I]BTX at a final concentration of 10 nM
was added directly to each well and incubated for 2 h. Cells were
washed three times gently with K+-Ringer's
buffer (140 mM KCl, 5.4 mM NaCl, 1.8 mM CaCl2,
1.7 mM MgCl2, 25 mM HEPES, 0.03 mg/ml bovine
serum albumin, pH 7.4) and 1 ml of 1 M NaOH was added to each well to
lyse the cells. Cell lysates were counted in a gamma counter and
protein was assayed in the cell lysates with BCA reagents.
Run-On Transcriptional Analysis.
Nuclei were isolated from
cultured cells and stored at
70°C as described previously (Luo et
al., 1994
). Nuclei (200 µl) were thawed and mixed with equal volume
of 2× buffer containing 10 mM Tris-HCl, pH 8.0; 5 mM
MgCl2; 0.3 M KCl; 5 mM dithiothreitol; 1 mM each
of ATP, GTP and CTP; and 10 µl of
32P-
-UTP. Radiolabelled mRNA was transcribed,
isolated, and hybridized for at least 36 h at 65°C to slot blots
containing 5 µg of each plasmid DNA. A 1.7-kilobase cDNA fragment
within the coding region of mouse
-nAChR subunit in a pSP-65 vector
was linearized with BamHI. A 1.4-kilobase cDNA fragment of
mouse
-tubulin in Bluescript SK II+ was
linearized with KpnI. Bluescript SK
II+ plasmid DNA linearized with EcoRI
or KpnI was used as control for the dsDNAs. For detecting
AChE mRNA, control M13 phage DNA and that containing a 2.3-kilobase
single-strand antisense AChE cDNA insert were used. After extensive
washing with 2× standard saline citrate buffer, radioactivity was
determined by autoradiography and densitometry.
Determination of AChE mRNA Stability.
C2-C12 cells
differentiated for 3 days in the presence or absence of 1 µM CsA were
treated with 30 µg/ml
5,6-dichloro-1-
-d-ribofuranosylbenzimidazole (DRB) to
block transcription and total RNA was extracted at the designated time
after treatment. The decay rate of AChE mRNA was then determined by
RNase protection with 50 µg of total RNA per lane. The AChE mRNA
half-lives calculated from these data could be overestimated because
slight reductions in the amount of total RNA occurred at longer times
after DRB treatment; use of a constant amount of total RNA per sample
contributes to the relatively high values in the later time points of
the curves (see Results). A GAPDH antisense probe was
included in all the experiments for normalization of sample loading for
each time point.
Western Blots. To examine the cellular levels of immunophilins or calcineurin, C2-C12 cells were washed three times with PBS and extracted in 50 mM Tris-HCl buffer, pH 8.0, containing 150 mM NaCl, 0.5% Triton, 1 mM EDTA, and mixture of protease inhibitors. After removal of an aliquot for protein assay, the extracts were subjected to polyacrylamide gel electrophoresis, and then transferred to nitrocellulose membranes (Schleicher & Schuell, Inc., Keene, NH) electrophoretically. After blocking nonspecific binding sites with 5% low-fat milk in PBS containing 0.1% of Tween-20, antibodies against specified proteins or peptides were used to blot the membrane in the same buffer for 1 h at room temperature. After washing the nitrocellulose membrane two times with the same buffer and one time with a buffer containing 150 mM NaCl and 50 mM Tris-HCl (pH 7.5), the antibody-protein complexes were blotted for 1 h at room temperature with secondary antibodies labeled with horseradish peroxidase in the buffer containing 5% low-fat milk. After extensive washing, the protein-antibody complexes were detected with chemiluminescent reagents (Amersham Corp.).
Construction of Recombinant Adenoviruses Containing Calcineurin
cDNAs.
Conventional transfection methods, such as calcium
phosphate or lipofectamine-mediated transfection, resulted in low
transfection efficiencies for C2-C12 cells. More importantly, the
transfected cells lost CsA responsiveness (Z.D.L., unpublished data),
presumably due to transient permeabilization and influx of
Ca2+. To overcome the transfection limitations,
adenoviruses containing either the constitutively active or the
dominant negative recombinant calcineurin constructs were used to
infect these cells. The constitutively active construct encodes a
truncated calcineurin catalytic subunit (CnA
CaM-AI) that lacks the
sequences encoding the functional calmodulin-binding and autoinhibitory
domains (O'Keefe et al., 1992
). This construct was designed to mimic
proteolysed forms of calcineurin known to have constitutive
calcium-independent phosphatase activity in vitro (Hubbard and Klee,
1989
; Werlen et al., 1998
). Overexpression of this truncated
calcineurin subunit in human Jurkat cell line also exhibits
Ca2+-independent, constitutive phosphatase
activity (O'Keefe et al., 1992
; Werlen et al., 1998
).
CaM-AI and pAdv/HA-BKO were constructed
by inserting an EcoRI fragment containing HA-CnA
CaM-AI or HA-BKO coding sequences from the pSR
3/HA-CnA
CaM-AI or
pSR
3/HA-BKO plasmids, respectively, into the EcoRI site
of the pAC/CMV vector. The HA epitope was used to detect overexpression
of these constructs in Western blots because commercially available
anticalcineurin A antibodies recognize an epitope in the deleted region
of these constructs and therefore were not useful in our study. The HA tag at the N terminus does not affect the function of the constructs (data not shown) (Werlen et al., 1998
CaM-AI or
pAdv/HA-BKO in 293 cells (American Type Culture Collection). The
resulting adenoviruses were plaque purified and amplified in 293 cells. The genomic structure of the recombinant adenovirus was confirmed by
polymerase chain reaction analysis with oligonucleotides specific for
the insertion site at the E1a region. Recombinant adenoviruses were
prepared from CsCl density gradient ultracentrifugation. Titers were
determined from A260 with 1.0 absorbance
being equivalent to ~1012 particles/ml.
Infection of Calcineurin-Containing Recombinant Adenoviruses in
C2-C12 Myocytes.
Different dosages of adenovirus were added into
culture media to achieve specified multiplicity of infection. The
optimal time of infection during muscle differentiation was determined by detecting HA peptide expression in C2-C12 cells infected with pAdv/HA-CnA
CaM-AI between day 0 and day 2. Differentiating myocytes were infected more efficiently than undifferentiated myoblasts (see
Results), consistent with findings reported in other rodent muscle cell lines (Quantin et al., 1992
). In our experiments, cells
infected at day 1 of differentiation express the largest amounts of HA
peptides (see Results). This may result from two factors.
First, expression of integrin receptors, essential for the attachment
of adenovirus to host cells (Kohout et al., 1996
), is developmentally
regulated in C2-C12 cells (Collo et al., 1993
; Ziober and Kramer,
1996
). The difference in infection efficiencies may result from
different expression levels of integrin receptor subtypes mediating the
adenovirus infection. Second, when cells were infected at later stages
of differentiation (day 2 or 3) and harvested 2 days later, some mature
infected myotubes may have detached and died. Thus, cells at day 1 of
differentiation were used for all the infection experiments. Adenovirus
vector expressing
-gal was used in parallel infections (Wang et al., 1998
). After 16 h of infection, medium was removed and cells were incubated for an additional 2 days in fresh medium before extraction of
total RNA.
Statistical Analyses. Unpaired Student's t tests were performed where significance is indicated by a two-tailed P value < .05.
| |
Results |
|---|
|
|
|---|
Enhancement of AChE Expression by CsA in C2-C12 Cells during
Myogenesis.
CsA treatment caused concentration-dependent increases
in the expression of AChE in differentiating C2-C12 cells (Fig.
1). The half-maximal enhancement occurred
at ~300 nM, a concentration that correlates well with the
Kd value in binding studies (200 nM;
Handschumacher et al., 1984
). In contrast, tacrolimus, another immunosuppressive agent active in the subnanomolar concentration range
in other systems (Bierer et al., 1990
), had little influence on AChE
expression. Treatment with rapamycin, a structurally distinct immunosuppressant, in the subnanomolar concentration range resulted in
inhibition of cell growth and differentiation followed by substantial reduction of AChE expression (data not shown). Furthermore, treatment with CsH, an inactive analog of CsA, did not alter AChE expression (Fig. 1).
|
|
|
-BTX binding sites on the
nAChR, whose increased expression roughly parallels that of AChE upon
differentiation of C2-C12 cells, were not altered by CsA treatment
(Fig. 3B).
As shown in Fig. 4 and summarized in Fig.
5, AChE and nAChR mRNA increase
substantially during muscle terminal differentiation. The parallel
sequential increases of functional AChE and nAChR indicate that the
increased expression of both proteins reflects the availability of
their transcripts (compare Figs. 3 and 5). CsA treatment during muscle
differentiation only augments AChE mRNA levels, but not mRNA levels of
the
-nAChR subunit (Figs. 4 and 5). The mouse Ache gene
has two polyadenylation signals separated by 1.1 kilobase (Li et al.,
1993
|
|
Run-On Transcriptional Rates of Ache Gene Were Not Altered by
CsA.
To examine whether the CsA-induced increases in AChE
expression are due to enhanced transcription of the Ache
gene, transcriptional rates of Ache and
-nAchR
genes were examined. As indicated in Fig.
6, treatment of 1 µM CsA in
differentiating C2-C12 cells did not affect run-on transcriptional
rates of the Ache and
-nAchR genes.
|
CsA Increases AChE mRNA Stability in C2-C12 Cells.
Because
CsA treatment did not enhance run-on transcriptional rates of the
Ache gene, the CsA-induced AChE mRNA expression may be due
to increased stability of the transcripts. To test this hypothesis,
rates of AChE mRNA degradation were examined in cells treated with or
without CsA after blocking transcription with DRB, an adenosine analog
that specifically inhibits RNA polymerase II (Tamm et al., 1976
). As
indicated in Fig. 7, the estimated AChE
mRNA half-life in 3-day-differentiated myotubes was ~8 h, a value
similar to that reported previously (Fuentes and Taylor, 1993
). CsA
treatment increased the estimated half-life of AChE mRNA to ~16 h.
|
Intracellular Immunophilin and Calcineurin Levels in C2-C12
Cells.
Certain cell lines are known to be deficient in tacrolimus
binding proteins (Kaye et al., 1992
). To ascertain whether the differential effects of CsA and tacrolimus on AChE expression were due
to different levels of intracellular receptors for these agents in
C2-C12 cells, we examined the concentrations of cyclophilin A, the
receptor for CsA, and FKBP12, the receptor for tacrolimus, in C2-C12
cells. Western blot analyses indicate that myoblasts and myotubes
express similar levels of cyclophilin A and FKBP12. However,
calcineurin expression is low in myoblasts, but increases >3-fold upon
muscle differentiation (Fig. 8).
|
Influence of Overexpressed Calcineurin Mutants on AChE
Expression.
Because cyclophilin is expressed in myoblasts and
myotubes at comparable high cellular concentrations, its regulation is
less likely to be responsible for the CsA induction than calcineurin, whose expression associated with muscle differentiation is enhanced >3-fold. To test this hypothesis, overexpression of constitutively active (HA-CnA
CaM-AI) or dominant negative (HA-BKO) calcineurin constructs was sought. As indicated in Fig. 2, C and D, adenovirus infect nearly 100% of the C2-C12 cells and infection does not affect
cell differentiation as indicated by the normal muscle morphology of
infected cells. Infected differentiating C2-C12 cells express the
calcineurin constructs well as indicated by expression of a large
amount of the HA peptide (Fig. 9). Muscle morphology also was not altered in cells overexpressing calcineurin (data not shown). If CsA enhancement of AChE mRNA level is mediated by
calcineurin inhibition, then calcineurin, perhaps through its phosphatase activity, may play a role in destabilizing AChE mRNA during
myogenesis. If this is the case, overexpression of HA-CnA
CaM-AI should reduce AChE mRNA levels in differentiating cells, and its effect
should be blocked by CsA treatment. Conversely, overexpression of
HA-BKO should increase AChE mRNA levels in differentiating cells and
its effect should be further enhanced by CsA treatment. These
predictions are generally supported by our findings shown in Fig.
10. Overexpression of HA-CnA
CaM-AI
in untreated differentiating myotubes resulted in a 59% reduction of
AChE mRNA compared with mock-infected, untreated myotubes
(P < .001). This calcineurin-induced inhibition was
blocked by CsA treatment (P < .001) at concentrations that should be expected to inhibit both the endogenous and mutant calcineurins expressed after infection. In contrast, overexpression of
HA-BKO in untreated differentiating myotubes caused a 48% increase of
AChE mRNA compared with mock-infected, untreated myotubes
(P < .05), which was further enhanced by CsA treatment
(P < .05) (a total of 140% increase over
mock-infected, untreated myotubes), indicative of CsA possessing the
capacity to inhibit the residual calcineurin activity.
|
|
| |
Discussion |
|---|
|
|
|---|
Our findings indicate that treatment of CsA in differentiating
C2-C12 muscle cells enhances differentiation-induced expression of
AChE, but not nAChR. The enhancement is seen at both the level of AChE
mRNA and gene product (Figs. 1, 3-5) indicating that CsA primarily
influences transcript production or its stabilization. Previous studies
analyzing run-on transcription rates, transcription rates of
Ache-luciferase reporter gene constructs, superinduction of
AChE mRNA by inhibition of protein synthesis, and AChE mRNA degradation
rates all suggest that mRNA stabilization plays a critical role in
enhanced AChE expression associated with muscle differentiation
(Fuentes and Taylor, 1993
; Li et al., 1993
; Luo et al., 1994
). CsA
treatment does not increase the apparent transcriptional rate of the
Ache gene (Fig. 6), suggesting that CsA regulation is due
mainly to further enhancement of the stability of AChE mRNA during
differentiation. This is confirmed by the finding that CsA treatment
increases the estimated half-life of AChE mRNA (Fig. 7). Thus, a
CsA-sensitive pathway plays a role in the differentiation-induced stabilization of AChE mRNA.
The action of CsA appears to be specific for AChE expression and
requires its interaction with intracellular cyclophilins. These
conclusions are supported by the following observations. The
EC50 of the CsA action (300 nM) correlates well
with the Kd value (200 nM) for its binding
to cyclophilins (Fig. 1; Handschumacher et al., 1984
). In addition, CsA
treatment selectively enhances expression of AChE, but not nAChR whose
expression is enhanced by transcriptional activation during myogenesis
(Evans et al., 1987
; Baldwin and Burden, 1988
). Furthermore, the action
of CsA is reversible because treated cells show a normal rate of AChE expression during myogenesis after CsA was removed (Fig. 3). Finally, CsH, an inactive analog of CsA, and tacrolimus, another
immunosuppressive agent, neither of which bind to cyclophilins
(Handschumacher et al., 1984
; Harding et al., 1989
; Siekierka et al.,
1989
), do not influence AChE expression (Fig. 1). The inability of
tacrolimus to enhance AChE expression is not due to the absence of
intracellular receptors as observed for mast cells (Kaye et al., 1992
)
because FKPB12 can be detected in both myoblasts and myotubes (Fig. 8).
Myoblast differentiation is restricted in G1
phase of the cell cycle (Clegg et al., 1987
). Even though CsA is known
to arrest the cell cycle in G0 phase in cells
such as lymphocytes (Schreiber and Crabtree, 1997
) and keratinocytes
(Karashima et al., 1996
), CsA action on AChE expression is not likely
to be associated with cell cycle arrest because treatment with CsA
before the induction of muscle differentiation does not increase AChE
mRNA expression (data not shown). In addition, CsA-treated muscle cells
display normal differentiation as assessed by their muscle fiber
morphology, fusion to myotubes (Fig. 2, A and B), creatine kinase
activity, and expression of nAChR (Figs. 3-5). Furthermore, when cells
were treated with CsA for 1 day, then allowed to differentiate for two
additional days in CsA-free medium, the AChE expression rate is similar
to that of control cells (Fig. 3A), consistent with CsA action being
associated with muscle differentiation, rather than the
immunosuppressant triggering an early event in differentiation.
It is known that CsA binds to its immediate downstream target
cyclophilin A and inhibits cis-trans proline
isomerase activity of cyclophilin (Harding et al., 1989
). However,
similar to immunosuppressant activities of this drug (Bierer et al.,
1990
), the influence of CsA on AChE mRNA seems independent of the
isomerase activity of cyclophilin. This is supported by the findings
that expression of cyclophilin A is independent of muscle
differentiation (Fig. 8), whereas the CsA action appears
differentiation-dependent. Furthermore, overexpression of cyclophilin A
does not increase AChE mRNA levels during myogenesis (Z.D.L.,
unpublished data).
CsA-cyclophilin and FK506-FKBP complexes are known to bind to a common
target calcineurin and therein inhibit its phosphatase activity (Liu et
al., 1991
). The correlation between differentiation-induced expression
of calcineurin (Fig. 8) and AChE (Figs. 3-5) suggests a role of
calcineurin in regulation of AChE mRNA. The down- or up-regulation of
AChE mRNA upon overexpression of the constitutively active or dominant
negative calcineurin constructs, respectively, in untreated cells
indicates a role for calcineurin in destabilizing AChE mRNA during
myogenesis (Fig. 10). This regulatory mechanism may serve to control
enhanced biosynthesis of AChE during myogenesis, which has a long
half-life of ~50 h (Rotundo and Fambrough, 1980
). Because the effects
of constitutively active or dominant negative calcineurin on AChE mRNA
can be reversed or enhanced, respectively, by CsA treatments (Fig. 10),
it is likely that the CsA-induced stabilization of AChE mRNA is
mediated through inhibition of calcineurin. The similar increases of
AChE mRNA in CsA-treated cells with or without overexpression of the
calcineurin constructs indicate that CsA at this concentration (1 µM)
may have elicited close-to-maximal inhibition of endogenous and
exogenous calcineurin activities, thus, achieving a near maximal
increase in AChE mRNA (Fig. 10).
The inability of tacrolimus to produce the same response as CsA (Fig.
1) suggests that the phosphatase activity of calcineurin per se may not
be the sole determinant of CsA-induced AChE expression. Specificity for
a particular phosphoprotein and/or a downstream association responsive
to the CsA-cyclophilin-calcineurin complex, but not to that of
FK506-FKBP12-calcineurin, may govern the CsA response in muscle. This
hypothesis is supported by the notion that phosphatases exhibit
substrate selectivity by recognizing three-dimensional patches on
phosphoproteins remote from the dephosphorylation site (Schreiber,
1992
). For example, these drug-immunophilin complexes inhibit
phosphatase activity of calcineurin toward phosphopeptide and
phosphoprotein substrates, yet they cause a 2- to 3-fold activation of
phosphatase activity toward a small substrate, p-nitrophenyl phosphate (Liu et al., 1991
). Thus, the catalytic site of the inhibited
calcineurin is still accessible to small substrates, suggesting that
the binding of drug-immunophilin complexes to an allosteric rather than
the active site of calcineurin modulates substrate selectivity. In
addition, CsA-cyclophilin A and FK506-FKBP12 bind to distinct, highly
conserved regions of calcineurin A (Cardenas et al., 1995
), which may
cause distinct conformational changes of the enzyme and result in
different binding affinities for downstream targets. This behavior was
found for phosphatase 2A where replacement of its regulatory subunit by
the small T antigen of simian virus 40 results in alteration of its
substrate specificity and cellular localization (Mumby and Walter,
1991
).
Collectively, our studies suggest that calcineurin-mediated
dephosphorylation is an important component in the calcium-sensitive regulation of AChE mRNA stability (Luo et al., 1994
, 1996
).
Dephosphorylation may serve to activate destabilizing factors or
inactivate stabilizing factors, which are involved in governing AChE
mRNA lifetimes during myogenesis. These factors, however, may be
influenced by certain conformations of calcineurin complexes induced by
CsA, but not FK506. In fact, emerging data support an integrated,
calcium-calmodulin-dependent pathway in regulation of AChE mRNA
stability. For example, intracellular immunophilins are found to serve
as accessory proteins of ryanodine receptors to modulate intracellular
calcium (Timerman et al., 1993
; Brillantes et al., 1994
). In addition,
calmodulin regulates intracellular calcium channel activity by
interacting with several cytoplasmic domains of the ryanodine receptors
(Wagenknecht et al., 1997
), which are known to play an important role
in the calcium-sensitive regulation of AChE mRNA stability during
myogenesis (Luo et al., 1994
). Our study suggests that calcineurin may
be an important mediator of the regulation.
| |
Footnotes |
|---|
Received April 1, 1999; Accepted August 5, 1999
1 Current address: Basel Institute for Immunology, Grenzacherstrasse 487, CH-4005, Basel, Switzerland.
This study was supported by National Institutes of Health (Grants GM 18360 to P.T., F32HL09848 to Z.D.L., and HL46345 to K.R.C.) and a grant from the Muscular Dystrophy Association to P.T. G.W. was supported by the Swiss Academy of Medical Sciences and the Swiss National Science Foundation (Grant 823A-046706). The Basel Institute for Immunology was founded and is supported by F. Hoffman-La Roche Ltd., Basel, Switzerland.
Send reprint requests to: Dr. Palmer Taylor, Department of Pharmacology, Basic Science Bldg./0636, University of California-San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0636. E-mail: priley{at}ucsd.edu
| |
Abbreviations |
|---|
AChE, acetylcholinesterase;
nAChR, nicotinic
acetylcholine receptor;
CsA, cyclosporin A;
CsH, cyclosporine H;
BCA, bicinchoninic acid;
-BTX,
-bungarotoxin;
HA, hemagglutinin;
DFP, diisopropyl fluorophosphate;
GAPDH, glyceraldehyde 3-phosphate
dehydrogenase;
-gal,
-galactosidase;
CnA
CaM-AI, constitutively
active calcineurin catalytic construct;
DRB, 5,6-dichloro-1-
-d-ribofuranosylbenzimidazole;
BKO, B
subunit knock out construct;
Adv, adenovirus.
| |
References |
|---|
|
|
|---|
-subunit gene: Identification of a 148-bp cis-acting region that confers myotube specific expression.
J Cell Biol
107:
2271-2279
receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: Resistance to FK 506 is associated with a deficiency in FK 506-binding protein FKBP12.
Proc Natl Acad Sci USA
89:
8542-8546
to activate JNK and IL-2 promoter in T lymphocytes.
EMBO J
17:
3101-3111[Medline].This article has been cited by other articles:
![]() |
J. V. Chakkalakal, P. Miura, G. Belanger, R. N. Michel, and B. J. Jasmin Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signaling Nucleic Acids Res., February 11, 2008; 36(3): 826 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Mu, L. D. Brown, Y. Liu, and M. F. Schneider Roles of the calcineurin and CaMK signaling pathways in fast-to-slow fiber type transformation of cultured adult mouse skeletal muscle fibers Physiol Genomics, August 20, 2007; 30(3): 300 - 312. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pregelj, M. Trinkaus, D. Zupan, J. J. Trontelj, and J. Sketelj The Role of Muscle Activation Pattern and Calcineurin in Acetylcholinesterase Regulation in Rat Skeletal Muscles J. Neurosci., January 31, 2007; 27(5): 1106 - 1113. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Deschenes-Furry, K. Mousavi, F. Bolognani, R. L. Neve, R. J. Parks, N. I. Perrone-Bizzozero, and B. J. Jasmin The RNA-Binding Protein HuD Binds Acetylcholinesterase mRNA in Neurons and Regulates its Expression after Axotomy J. Neurosci., January 17, 2007; 27(3): 665 - 675. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sun, H. C. Blair, Y. Peng, N. Zaidi, O. A. Adebanjo, X. B. Wu, X. Y. Wu, J. Iqbal, S. Epstein, E. Abe, et al. Calcineurin regulates bone formation by the osteoblast PNAS, November 22, 2005; 102(47): 17130 - 17135. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. K. Tung, R. C. Y. Choi, N. L. Siow, J. X. S. Jiang, K. K. Y. Ling, J. Simon, E. A. Barnard, and K. W. K. Tsim P2Y2 Receptor Activation Regulates the Expression of Acetylcholinesterase and Acetylcholine Receptor Genes at Vertebrate Neuromuscular Junctions Mol. Pharmacol., October 1, 2004; 66(4): 794 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. C. Lee, R. C. Y. Choi, A. K. L. Ting, N. L. Siow, J. X. S. Jiang, J. Massoulie, and K. W. K. Tsim Transcriptional Regulation of Acetylcholinesterase-associated Collagen ColQ: DIFFERENTIAL EXPRESSION IN FAST AND SLOW TWITCH MUSCLE FIBERS IS DRIVEN BY DISTINCT PROMOTERS J. Biol. Chem., June 25, 2004; 279(26): 27098 - 27107. [Abstract] [Full Text] |